TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04508738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERP
Description: The ERP intervention is applied in a randomized and counter-balanced order across visits 2-4 in each 3-min break in-between the six 30-s sprints, with one intervention per visit. The order and timing of the constituents of the interventions will be strictly constant within and between participants.~ERP: 1) neck cooling with an iced gel pad, 2) drinking a ∼ 6% CHO solution, 3) mouth-rinsing with a ∼10% CHO, ∼6 mg ･ kg -1 caffeine solution, 4) performing submaximal squats and 5) hyperventilating a hyperoxic mixture

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control intervention is applied in a randomized and counter-balanced order across visits 2-4 in each 3-min break in-between the six 30-s sprints, with one intervention per visit. The order and timing of the constituents of the interventions will be strictly constant within and between participants.~1) neck cooling with room temperature gel pack, 2) drinking an artificially sweetened solution, 3) mouth-rinsing with artificially sweetened solution (containing no caffeine), 4) performing unloaded squat manoeuvres, 5) deep breaths with room air
Study: NCT02051322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jet Nebulizer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trunk Mask Nebulizer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobika Nebulizer
Study: NCT03308994

Intervention type: OTHER
Intervention: Delay between MS onset and introduction of first line DMT
Description: Delay between MS onset and introduction of first line DMT : time between date of MS onset ( the first demyelinating neurological events clinically defined) and date of the introduction of the first-line oral DMT (Interferons, Glatiramer Acetate, Dimethyl Fumarate and Teriflunomide)

Intervention type: OTHER
Intervention: Delay between MS onset and introduction of first line DMT
Description: Delay between MS onset and introduction of first line DMT : time between date of MS onset ( the first demyelinating neurological events clinically defined) and date of the introduction of the first-line oral DMT (Interferons, Glatiramer Acetate, Dimethyl Fumarate and Teriflunomide)

Intervention type: OTHER
Intervention: EDI
Description: For all cases of multiple sclerosis residence's places of each patient were geolocalized with a Geographic Information System (ARCGIS 10.2) and assigned to an IRIS, IRIS (Ilots Regroupés pour l'Information Statistique) is the smallest French geographic unit for which census data are available and EDI score was calculated for each IRIS. In order to attribute a social deprivation score to the IRIS, we used the French EDI (European Deprivation Index). EDI stands as a continuous variable but EDI will be used as a categorical variable in order to increase the comparability with others studies, so EDI is distributed into quintiles calculated at the French level.

Intervention type: OTHER
Intervention: EDI
Description: For all cases of multiple sclerosis residence's places of each patient were geolocalized with a Geographic Information System (ARCGIS 10.2) and assigned to an IRIS, IRIS (Ilots Regroupés pour l'Information Statistique) is the smallest French geographic unit for which census data are available and EDI score was calculated for each IRIS. In order to attribute a social deprivation score to the IRIS, we used the French EDI (European Deprivation Index). EDI stands as a continuous variable but EDI will be used as a categorical variable in order to increase the comparability with others studies, so EDI is distributed into quintiles calculated at the French level.
Study: NCT02051348

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pylopass
Description: Pylopass

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pylopass
Description: Pylopass

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01748721

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-endosialin/TEM1 monoclonal antibody MORAb-004
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT00888953

Intervention type: OTHER
Group type: OTHER
Intervention: Fall risk assessment
Description: Assessment of presence of risk factors (previous falls, self efficacy, balance and gait disorders, weakness, daily living impairment, limb pain, foot problems, dizziness, cognitive impairment, vision impairment, depression, urinary incontinence, heart disease, polimedication and consumption of neuroleptics and psychotropic medication)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fall risk assessment
Description: Assessment of presence of risk factors (previous falls, self efficacy, balance and gait disorders, weakness, daily living impairment, limb pain, foot problems, dizziness, cognitive impairment, vision impairment, depression, urinary incontinence, heart disease, polimedication and consumption of neuroleptics and psychotropic medication)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored intervention
Description: Induction of an intervention for each identified risk factor. If is possible the intervention will be directed towards the treatment of the underlying cause.
Study: NCT03778450

Intervention type: DRUG
Intervention: Analgesics, Opioid
Description: Patients are included in the long-term opioid group if they started an opioid-therapy between 2013 and 2017 and received consecutive prescriptions for opioid medications over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The treatment will be assessed using the ATC codes of opioid~treatment N02AA01, N02AA05, N02AB03, N02AE01, N02AX02, N02AX01, N02AX06) reported in reimbursed medicines to patients.

Intervention type: DRUG
Intervention: Non-Opioid Analgesic
Description: Patients with non-opioid pain medication are included, if they received a medication therapy with anticonvulsants (gabapentin, pregabalin, carbamazepine), antidepressants or non-opioid analgesics (NSAIDs, Metamizole) over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The non-opioid treatment will be assessed using the ATC codes (N03AX12, N03AX16, N03AF01) of treatment reported in reimbursed medicines to patients.
Study: NCT02503150

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APDC + Chemotherapy
Description: Patients in Arm APDC+Chemotherapy receive maximum 12 cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1,and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours).On day 8 of cycle1-3 and 7-9, patients also receive APDC vaccine infusion in 100ml saline. After 12 cycles, patients in Arm APDC+chemotherapy will receive 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks) plus APDC therapy (once every 3 months). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Patients in Arm Chemotherapy receive maximum 12cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1, and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours). After 12 cycles, patients in Arm chemotherapy will receive only 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
Study: NCT00166439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)
Description: rituximab 375 mg/m2 IV Weekly x 4 1 cycle only~dexamethasone 40 mg PO/IV Days 2-5 q 21 days 2 cycles~oxaliplatin 130 mg/m2 IV Day 2 q 21 days 2 cycles~cytosine arabinoside 2000 mg/m2 x 2 doses IV Days 2-3 q 21 days 2 cycles~pegfilgrastim 6 mg SQ Day 4 q21 days 2 cycles
Study: NCT02434042

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BB536
Description: Intervention consists of daily administration of 1g probiotic Bifidobacterium longum BB536, administer daily for five days a week at a fixed dosage of 9 log CFU/day for BB536 and continue for 10 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention consists of daily administration of 1g of 100% dextrin, administer daily for five days a week and continue for 10 months.
Study: NCT04594213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% NaCl.
Study: NCT02396355

Intervention type: DEVICE
Intervention: Investigational BD FACSPresto System
Description: Blood samples will be tested on the BD FACSPresto system for CD4 absolute count (CD4Abs), %CD4, and Hb concentration.

Intervention type: DEVICE
Intervention: BD FACSCalibur flow cytometer
Description: Blood samples will be tested on the predicate, currently marketed device. For CD4Abs and %CD4 measurement, the BD FACSCalibur flow cytometer will be used with BD Multiset software version 1.1 or later and BD Tritest CD3/CD4/CD45 reagent with Trucount tubes.

Intervention type: DEVICE
Intervention: Sysmex hematology analyzer KX-21
Description: Blood samples will be tested for hemoglobic concentration on the predicate, currently marketed Sysmex hematology analyzer KX-21
Study: NCT03516669

Intervention type: DRUG
Group type: OTHER
Intervention: Clarithromycin
Description: Twenty patients receive intraluminal clarithromycin eradication of H. pylor.

Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin, Clarithromycin
Description: Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with triple therapy which contains a proton pump inhibitor, amoxicillin and clarithromycin for 14 days.
Study: NCT00516256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHESS System
Description: Internet-based computer program for 6 months.
Study: NCT04254614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalised mobile application for IBD patients
Description: Patients will use a mobile application for ±6months (exact period depends on interval of biologic treatment) with the following functionalities:~* Personal interactive timeline to prepare for biologic treatment with reminders for blood tests, a questionnaire to exclude contra-indications for biologic treatment (e.g. current infection) and a message from the gastroenterology nurse when blood tests results and the questionnaire have been checked. Only in case of abnormal results or answers patients will be contacted by telephone by their gastroenterology nurse, which is currently standard care.~* Information about the patients' diagnosis and biologic treatment.~* General information on e.g. IBD treatment, vaccinations, frequently used medical terms, preparing for outpatient visits, what to do in case of disease symptoms.~Patients will fill in a questionnaire to measure study outcomes at baseline and at the end of the study period.
Study: NCT01802775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: edoxaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study: NCT02051348

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00516256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer Information Mentor
Description: Phone calls to the patient for 6 months.
Study: NCT04573036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS4800 tablets
Description: single oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS4800 tablets
Description: single oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS4800 tablets
Description: single oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS4800 tablets
Description: single oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS4800 tablets
Description: single oral administration
Study: NCT04284072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor Dot
Description: Multimodal (EEG, ECG, EMG and motion) seizure monitoring with Sensor Dot to complement EMU-based video-EEG monitoring (EMU Phase), and optional home-based seizure diary logging (Home Phase).
Study: NCT04573036

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: single oral administration
Study: NCT01528605

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high lutein
Description: one gelatine capsule containing 20mg lutein per day, for 96 weeks
Study: NCT01529359

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactibiane Tolerance
Description: Probiotics combination 2 gelules per days during 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 gelules per days for 6 weeks
Study: NCT04594213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% NaCl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% NaCl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% NaCl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% NaCl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).
Study: NCT01641367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Participants were administered darunavir orally as one 600 mg tablet twice a day (1200 mg per day) with food (taken with Ritonavir 100 mg twice a day \[200 mg per day\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Participants were administered darunavir orally as one 600 mg tablet twice a day (1200 mg per day) with food (taken with Ritonavir 100 mg twice a day \[200 mg per day\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Participants were administered darunavir orally as one 600 mg tablet twice a day (1200 mg per day) with food (taken with Ritonavir 100 mg twice a day \[200 mg per day\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Participants were administered darunavir orally as one 600 mg tablet twice a day (1200 mg per day) with food (taken with Ritonavir 100 mg twice a day \[200 mg per day\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine
Description: Patients were administered Etravirine orally as two 100 mg tablets or one 200 mg tablet twice a day (400 mg per day) following a meal.
Study: NCT02627157

Intervention type: DEVICE
Intervention: Dynamic Scheimpflug Analyzer
Description: Measurements of Corneal Biomechanical Properties Using a Dynamic Scheimpflug Analyzer
Study: NCT00622310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking exercise
Description: Subjects will be randomly assigned to either a structured, vigorous-intensity endurance exercise training program or an intermittent, low-intensity exercise program. Individualized exercise prescriptions will be designed to target an increase of 2500 kcal/wk, and the theoretical weight loss will be approximately 15 pounds (\~6.8 kg) during the 6 month intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking exercise
Description: Subjects will be randomly assigned to either a structured, vigorous-intensity endurance exercise training program or an intermittent, low-intensity exercise program. Individualized exercise prescriptions will be designed to target an increase of 2500 kcal/wk, and the theoretical weight loss will be approximately 15 pounds (\~6.8 kg) during the 6 month intervention.
Study: NCT00241891

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Single behavior intervention
Description: Focused on changing beverage choices which may have a significant impact on weight.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Multiple behavior interventions
Description: Focused on multiple behaviors (nutrition, beverages, physical activity, and sedentary lifestyle) which may have a significant impact on weight.
Study: NCT01528605

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lutein plus zeaxanthin
Description: one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high zeaxanthin
Description: one gelatine capsule containing 10mg zeaxanthin per day, for 48 weeks
Study: NCT00241891

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Intervention unrelated to weight
Description: Focused on standard intervention strategies unrelated to weight including bullying prevention.
Study: NCT04360538

Intervention type: OTHER
Intervention: Quality of Life
Description: Physical disability assessment tool

Intervention type: OTHER
Intervention: Quality of Life
Description: Physical disability assessment tool

Intervention type: OTHER
Intervention: Impact Event Score
Description: Psychological Sequelae assessment tool

Intervention type: OTHER
Intervention: Hospital anxiety and depression scale
Description: Psychological Sequelae assessment tool
Study: NCT01641367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: Patients were administered FTC/TDF orally as one fixed dose combination tablet (FTC 200 mg/TDF 300 mg) once daily, with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Participants were administered Raltegravir orally as one 400 mg tablet twice daily (800 mg per day), with or without food
Study: NCT01917149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Study: NCT01463306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin administered as either capsule or liquid oral formulations. Subjects \<4 years of age at Visit 1 will receive study medication 3 times daily (TID) in equally divided doses. Subjects who are ≥4 years of age at Visit 1 will receive study medication twice daily (BID) in equally divided doses. Children less than 17 years of age will receive from 2.5 mg/kg/day to 10.0 mg/kg/day (maximum 600 mg/day. Adults 17 and older will receive from 150 mg/day to 600 mg/day.
Study: NCT03316703

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional open surgery
Description: Surgical treatment will be performed by stabilizing the fractured vertebral segment (proximal vertebra and vertebra distal to fractured vertebra and fractured vertebra) by means of a 6.5 mm or 6.5 mm diameter polyaxial pedicle screw system. In the fractured proximal and distal vertebrae to the vertebrae, screws will be used up to the vertebral body and fractured vertebra will use shorter screws that do not penetrate the vertebral body. In the fractured vertebra, single or bilateral pedicle screw will be used according to the degree of involvement of the pedicle of the fractured vertebra.~The vertebral fixation system will be applied through the conventional open approach (group A).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive percutaneous surgery
Description: Surgical treatment will be performed by stabilizing the fractured vertebral segment (proximal vertebra and vertebra distal to fractured vertebra and fractured vertebra) by means of a 6.5 mm or 6.5 mm diameter polyaxial pedicle screw system. In the fractured proximal and distal vertebrae to the vertebrae, screws will be used up to the vertebral body and fractured vertebra will use shorter screws that do not penetrate the vertebral body. In the fractured vertebra, single or bilateral pedicle screw will be used according to the degree of involvement of the pedicle of the fractured vertebra.~The vertebral fixation system will be applied through the minimally invasive percutaneous approach (group B) according to allocation after randomization.
Study: NCT04266925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 referees present
Description: We compared player behavior with one versus three referees present on youth soccer fields during match play. The time between these two matches ranged from a few hours to several weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1 referee present
Description: We compared player behavior with one versus three referees present on youth soccer fields during match play. The time between these two matches ranged from a few hours to several weeks.